RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial

IMPORTANCE: In neoadjuvant trials, treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancers with dual HER2 blockade resulted in increased pathologic complete response (pCR) rates compared with each targeted agent alone. Amplification and/or overexpression of HER2 currentl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Fumagalli, Debora, Venet, David, Ignatiadis, Michail, Azim, Hatem A., Maetens, Marion, Rothé, Françoise, Salgado, Roberto, Bradbury, Ian, Pusztai, Lajos, Harbeck, Nadia, Gomez, Henry, Chang, Tsai-Wang, Coccia-Portugal, Maria Antonia, Di Cosimo, Serena, de Azambuja, Evandro, de la Peña, Lorena, Nuciforo, Paolo, Brase, Jan C., Huober, Jens, Baselga, José, Piccart, Martine, Loi, Sherene, Sotiriou, Christos
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5374044/
https://ncbi.nlm.nih.gov/pubmed/27684533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2016.3824
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados